JNK/p38 MAPK Signaling Pathway in Neurodegeneration

JNK/p38 MAPK Signaling Pathway in Neurodegeneration

Overview

The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) families represent critical stress-activated signaling pathways that play pivotal roles in the pathogenesis of neurodegenerative diseases. These serine/threonine kinases are activated by diverse cellular stresses including oxidative stress, inflammatory cytokines, glutamate excitotoxicity, and pathological protein aggregates, leading to downstream effects on neuronal survival, synaptic function, and glial activation[@jnk2023].

The JNK and p38 MAPK pathways serve as central integrators of cellular stress signals, coordinating responses that range from adaptive survival mechanisms to programmed cell death. In the context of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), these pathways are chronically activated, contributing to progressive neuronal dysfunction and death. Understanding the specific roles of JNK and p38 isoforms in different cell types and disease contexts has revealed potential therapeutic targets that are actively being explored in preclinical and clinical studies[@jnk2022][@mapk2021].

Historical Context and Discovery

JNK/p38 MAPK Signaling Pathway in Neurodegeneration

Overview

The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) families represent critical stress-activated signaling pathways that play pivotal roles in the pathogenesis of neurodegenerative diseases. These serine/threonine kinases are activated by diverse cellular stresses including oxidative stress, inflammatory cytokines, glutamate excitotoxicity, and pathological protein aggregates, leading to downstream effects on neuronal survival, synaptic function, and glial activation[@jnk2023].

The JNK and p38 MAPK pathways serve as central integrators of cellular stress signals, coordinating responses that range from adaptive survival mechanisms to programmed cell death. In the context of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), these pathways are chronically activated, contributing to progressive neuronal dysfunction and death. Understanding the specific roles of JNK and p38 isoforms in different cell types and disease contexts has revealed potential therapeutic targets that are actively being explored in preclinical and clinical studies[@jnk2022][@mapk2021].

Historical Context and Discovery

The MAPK signaling cascade was first characterized in the early 1990s as a fundamental cellular signaling pathway responding to extracellular stimuli. The JNK family was originally identified as a kinase that phosphorylates the transcription factor c-Jun in response to UV radiation and other cellular stresses. Subsequent research revealed that JNK and p38 pathways play essential roles in development, stress responses, and cell fate decisions. The involvement of these pathways in neurodegeneration was first demonstrated in the late 1990s, when researchers observed elevated JNK activation in post-mortem brain tissue from AD and PD patients[@kim2019].

Key discoveries that shaped our understanding include:

• 1998: Identification of JNK3 as the neuron-specific isoform critical for excitotoxic neuronal death
• 2001: Demonstration that p38 MAPK mediates cytokine-induced neuronal apoptosis
• 2004: Evidence for JNK-mediated mechanism in mutant SOD1-induced motor neuron degeneration
• 2010: Development of selective JNK inhibitors entering clinical trials for AD
• 2015: Understanding of ASK1 as upstream activator linking mitochondrial stress to JNK/p38 activation
• 2020-2024: Clinical trials of JNK and p38 inhibitors in neurodegenerative diseases

MAPK Family Overview

JNK Family

The JNK family consists of three genes encoding ten isoforms through alternative splicing. JNK1 and JNK2 are expressed ubiquitously, while JNK3 is neuron-specific and exhibits the strongest involvement in neurodegenerative processes[@jnk2022a].

| Isoform | Gene | Tissue Distribution | Key Functions | Disease Relevance |
|---------|------|-------------------|---------------|------------------|
| JNK1α1/2 | MAPK8 | Ubiquitous | Stress response, cell proliferation, immune function | PD, AD |
| JNK2α1/2 | MAPK9 | Ubiquitous | Cell proliferation, differentiation | AD, MS |
| JNK3α1/2 | MAPK10 | Neuron-specific, heart | Neuronal apoptosis, excitotoxicity | AD, PD, ALS, HD |

The JNK signaling cascade is activated by upstream MAPK kinases MKK4 and MKK7, which phosphorylate JNK at Thr183 and Tyr185 residues. Activated JNK translocates to the nucleus where it phosphorylates transcription factors including c-Jun, JunD, ATF2, and Elk-1, leading to expression of pro-apoptotic genes and inflammatory mediators[@mehan2018].

p38 Family

The p38 MAPK family includes four isoforms (p38α, p38β, p38γ, p38δ) encoded by separate genes. p38α is the most widely expressed and studied isoform in the context of neurodegeneration, while p38β shows brain-enriched expression[@microglia2022].

| Isoform | Gene | Distribution | Functions | Disease Relevance |
|---------|------|--------------|------------|------------------|
| p38α | MAPK14 | Ubiquitous, high in brain | Inflammation, apoptosis, cytokine production | AD, PD, ALS |
| p38β | MAPK11 | Brain-enriched | Similar to α, more restricted | AD |
| p38γ | MAPK12 | Muscle, brain | Tissue-specific, development | Less clear |
| p38δ | MAPK13 | Lung, pancreas, brain | Tissue-specific functions | PD |

p38 MAPK is activated by MKK3 and MKK6, which phosphorylate p38 at Thr180 and Tyr182. The p38 pathway regulates numerous cellular processes including translation through MSK1/2 and MNK1/2, transcription through ATF2, CREB, and C/EBP, and cell survival through modulation of Bcl-2 family proteins and caspase activation[@tau2021].

Signaling Cascade Architecture

Role in Alzheimer's Disease

Amyloid-β Activation of JNK/p38 Pathways

Amyloid-beta (Aβ) peptide, the central pathogenic driver of Alzheimer's disease, activates both JNK and p38 MAPK pathways through multiple mechanisms. Aβ oligomers bind to various cell surface receptors including NMDA receptors, AMPA receptors, and cellular prion protein (PrP^C), triggering downstream MAPK signaling cascades[@activates2020].

Key mechanisms of Aβ-induced MAPK activation:

JNK-Mediated Neuronal Apoptosis

JNK3 plays a critical role in Aβ-induced neuronal apoptosis through multiple downstream effectors[@zhu2002]:

• c-Jun phosphorylation: JNK phosphorylates c-Jun at Ser63 and Ser73, enhancing AP-1 transcriptional activity and promoting expression of pro-apoptotic genes including Bim, FasL, and PUMA.
• Mitochondrial pathway: JNK phosphorylates Bcl-2 family proteins, promoting cytochrome c release and caspase-9 activation.
• p53 activation: JNK phosphorylates p53 at Ser15, enhancing its transcriptional activity and pro-apoptotic function.
• Synaptic dysfunction: JNK activation contributes to synaptic loss through phosphorylation of synaptic proteins and disruption of spine morphology.

p38 in Neuroinflammation and Tau Pathology

p38 MAPK, particularly the p38α isoform, is activated in microglia surrounding amyloid plaques and contributes to chronic neuroinflammation in AD[@tau2021]:

• Microglial activation: p38 drives production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 in microglia, creating a feed-forward inflammatory loop.
• Tau phosphorylation: p38 phosphorylates tau at multiple AD-relevant sites including Thr181, Ser202, Thr205, and Thr231, promoting tau aggregation and NFT formation.
• Synaptic plasticity impairment: p38-mediated phosphorylation of AMPA receptor subunits contributes to LTP deficits observed in AD models.
• Blood-brain barrier dysfunction: p38 activation in endothelial cells contributes to BBB breakdown and peripheral immune cell infiltration.

Clinical Evidence and Therapeutic Implications

Post-mortem studies of AD brain tissue reveal:

• Increased phospho-JNK levels in vulnerable brain regions (hippocampus, entorhinal cortex)
• Elevated phospho-p38 in microglia surrounding plaques
• Correlation between MAPK activation and disease severity
• JNK3 upregulation in neurons showing early tau pathology

| Compound | Target | Stage | Outcome |
|----------|--------|-------|---------|
| D-JNKI1 (Tat-JNK-IN-1) | JNK1/2/3 | Phase II | Showed neuroprotection in preclinical models |
| SP600125 | JNK1/2/3 | Preclinical | Not advanced to clinical trials |
| Losmapimod | p38α | Phase III | Failed to demonstrate cognitive benefit in AD |
| PH-797804 | p38α | Phase II | Terminated due to liver toxicity |
| Semapimod | p38α | Phase II | Limited efficacy |

The failure of p38 inhibitors in AD trials highlights the challenge of targeting highly pleiotropic pathways and suggests that timing of intervention, patient selection, and pathway specificity may be critical for success.

Role in Parkinson's Disease

Dopaminergic Neuron Vulnerability

The substantia nigra pars compacta (SNc) dopaminergic neurons exhibit particular vulnerability to JNK-mediated cell death in Parkinson's disease. Several factors contribute to this selective vulnerability[@jnk2022]:

α-Synuclein and JNK Activation

α-Synuclein aggregation, the hallmark pathological feature of PD, activates both JNK and p38 pathways:

• Direct aggregation stress: Oligomeric and fibrillar α-synuclein triggers cellular stress responses that activate MAPK pathways
• Endoplasmic reticulum stress: α-Synuclein accumulation in the ER activates the unfolded protein response and downstream JNK
• Oxidative stress: α-Synuclein aggregation promotes ROS production that activates stress-sensitive kinases
• Neuroinflammation: α-Synuclein released from neurons activates microglia through TLR2/TLR4, triggering p38-mediated cytokine production

MPTP and Toxin Models

The MPTP model of PD demonstrates that mitochondrial toxins potently activate JNK in dopaminergic neurons:

• Complex I inhibition: MPTP inhibits mitochondrial complex I, leading to ATP depletion, ROS production, and JNK activation
• Bcl-2 family interaction: JNK phosphorylates Bcl-2 and Bcl-xL, neutralizing their anti-apoptotic function
• p53 activation: MPTP-induced JNK activates p53, promoting expression of pro-apoptotic genes

Therapeutic Targeting in PD

| Compound | Target | Stage | Notes |
|----------|--------|-------|-------|
| D-JNKI1 | JNK1/2/3 | Preclinical | Protected dopaminergic neurons in MPTP model |
| CEP-1347 | Mixed lineage kinase | Phase II/III | Failed in PD clinical trial |
| SR-3306 | JNK3 | Preclinical | Neuroprotective in animal models |
| SD-169 | p38α | Preclinical | Reduced microglial activation |

The failure of CEP-1347 (a MLK inhibitor upstream of JNK) in the ADAGIO trial highlights the complexity of targeting these pathways clinically. However, more selective JNK3 inhibitors and better patient selection may improve outcomes.

Role in ALS

JNK in Motor Neuron Degeneration

JNK activation is a consistent finding in ALS models and patient tissue:

• SOD1 mutations: Mutant SOD1 proteins directly activate JNK pathway through gain-of-toxic-function mechanisms involving mitochondrial dysfunction and oxidative stress[@cao2004].
• TDP-43 pathology: TDP-43 aggregation, found in >95% of ALS cases, triggers cellular stress responses that activate JNK.
• Glutamate excitotoxicity: Enhanced excitability and impaired glutamate transport lead to chronic NMDA receptor activation and JNK-mediated apoptosis.
• Axonal transport defects: Disrupted axonal transport leads to accumulation of damaged organelles and stress signaling.

p38 in Glial Activation

In ALS, p38 MAPK plays a critical role in non-cell autonomous motor neuron death through glial activation:

• Microglial p38: Activated microglia produce pro-inflammatory cytokines (IL-1β, TNF-α, COX-2) through p38-dependent mechanisms, creating toxic milieu for motor neurons.
• Astrocyte p38: Astrocytic p38 activation contributes to secretion of toxic factors and impaired glutamate uptake.
• Disease progression: p38 activation in glia correlates with disease progression in SOD1 mouse models.

Therapeutic Strategies

| Target | Approach | Status |
|--------|----------|--------|
| JNK3 | Gene therapy with JNK3 ASO | Preclinical |
| p38α | Small molecule inhibitors | Preclinical |
| ASK1 | Selonsertib (ASK1 inhibitor) | Phase II for other indications |

Role in Huntington's Disease

Mutant Huntingtin and JNK

Mutant huntingtin (mHTT) protein directly interacts with and activates JNK signaling:

• Direct interaction: mHTT binds to JNK and its upstream activators, promoting pathway activation
• Transcriptional dysregulation: JNK-mediated phosphorylation of c-Jun alters gene expression patterns
• Synaptic pathology: JNK contributes to dendritic spine loss and synaptic dysfunction
• Energy metabolism: JNK affects mitochondrial function and energy production[@hu2018]

p38 in HD

p38 MAPK is activated in HD models and contributes to:

• Inflammatory responses in microglia and astrocytes
• Excitotoxic vulnerability
• mHTT phosphorylation and aggregation

Cross-Links to Related Mechanisms

The JNK/p38 MAPK pathways intersect with numerous other neurodegenerative mechanisms:

• [Oxidative Stress](/mechanisms/oxidative-stress): ROS activates ASK1 and downstream JNK/p38; JNK promotes ROS production through mitochondrial dysfunction
• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome-pathway-neurodegeneration): p38 activation in microglia promotes NLRP3 inflammasome assembly and IL-1β production
• [Apoptosis Pathways](/mechanisms/apoptosis-neurodegeneration): JNK3-mediated activation of intrinsic apoptotic pathway
• [Tau Pathology](/mechanisms/tau-phosphorylation-pathways): p38 phosphorylates tau at multiple AD-relevant sites
• [Alpha-Synuclein](/mechanisms/alpha-synuclein-aggregation): JNK contributes to α-synuclein phosphorylation at Ser129
• [ER Stress/UPR](/mechanisms/endoplasmic-reticulum-stress): ASK1-JNK signaling in ER stress responses
• [Glutamate Excitotoxicity](/mechanisms/excitotoxicity-pathway): JNK activated by NMDA receptor overactivation

Therapeutic Development

Challenges in MAPK Inhibitor Development

Promising Approaches

Biomarkers for MAPK Pathway Activation

Peripheral Biomarkers

• Phospho-JNK in peripheral blood mononuclear cells: Correlates with disease activity in PD
• Phospho-p38 in serum: Elevated in AD and correlates with cognitive decline
• c-Jun phosphorylation products: Detectable in plasma

CSF Biomarkers

• Phospho-JNK: Elevated in AD and PD
• p38 activation products: Correlates with neuroinflammation markers
• Neurofilament light chain: May be downstream of MAPK-mediated axonal injury

Imaging Biomarkers

• PET tracers for activated microglia: Indirect measure of p38-mediated neuroinflammation
• MR spectroscopy: Metabolic changes reflecting neuronal dysfunction

Genetic Associations

| Gene | Variant | Disease | Effect |
|------|---------|---------|--------|
| MAPK8 (JNK1) | -317A>G | PD | Altered expression |
| MAPK14 (p38α) | rs1885128 | AD | Modified risk |
| MAPK9 (JNK2) | rs3821977 | ALS | Altered function |
| MAPK8IP1 (JIP1) | Various | PD, AD | Altered JNK regulation |
| MAP3K5 (ASK1) | Various | PD | Modified susceptibility |

Future Directions

Current research focuses on:

Summary

The JNK and p38 MAPK signaling pathways represent critical mediators of neuronal dysfunction and death in neurodegenerative diseases. While these pathways serve essential physiological functions, their chronic activation by disease-relevant stressors promotes synaptic failure, neuronal apoptosis, and neuroinflammation. The development of selective brain-penetrant inhibitors and identification of biomarkers for patient selection remain active areas of research. Understanding the complex interplay between JNK/p38 activation and other disease mechanisms will be essential for effective therapeutic targeting.

References